I think this company's OS is incredibly low, and that shareholders will be exceptionally rewarded once regulatory approval is obtained, and we become revenue-producing.
I am very curious to see if our treatment population far surpasses what it would otherwise have been without breakthrough infections among the vaccinated. Will doctors and patients be anxious to continue with booster shots, if lenz becomes a viable treatment option?
News 
Market Data 
Discover 
